DOCSLIB.ORG

Budd-Chiari Syndrome: Current Perspectives and Controversies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Budd-Chiari Syndrome: Current Perspectives and Controversies Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2016; 20: 3273-3281 Budd-Chiari syndrome: current perspectives and controversies L. LIU 1, X.-S. QI 1,2 , Y. ZHAO 1, H. CHEN 1, X.-C. MENG 1, G.-H. HAN 1 1Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China 2Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang, China Lei Liu, Xingshun Qi, Yan Zhao, Hui Chen and Xiangchen Meng contributed equally to this work Abstract. – Budd-Chiari syndrome (BCS) is a jury of the sinusoidal wall 4. Given that BCS can rare disorder caused by hepatic venous outflow lead to potentially life-threatening liver failure obstruction with a wide spectrum of etiologies. and portal hypertension-related complications 1-4 , Clinical manifestations are so heterogeneous early diagnosis and treatment should be worth - that the diagnosis should be considered in any patients with acute or chronic liver disease. while. In the recent years, the number of publica - Therapeutic modalities for BCS have improved tions regarding BCS has been remarkably in - dramatically during the last few years. The con - creased 5. This paper aims to review the advances cept of a step-wise treatment strategy has been in the classification, etiology, diagnosis and treat - established, including anticoagulation, thrombol - ment of primary BCS. BCS secondary to malig - ysis, percutaneous recanalization, transjugular nant tumors, especially hepatocellular carcinoma, intrahepatic portosystemic shunt, surgery and liver transplantation. However, this strategy is is not considered as primary BCS. Their mecha - primarily based on experts’ opinions and retro - nisms should be mainly tumor invasion. spective case series, rather than prospective randomized trials. Furthermore, an earlier use of TIPS has been proposed in selected cases be - Classifications cause of a relatively high mortality from BCS pa - According to the potential causes, BCS can be tients who underwent medical therapy alone. classified as two groups: primary and secondary. Herein, we review the advances in the classifica - tion, etiology, clinical presentation, diagnosis BCS is considered primary when obstruction of and treatment of BCS. the hepatic venous outflow tract is the result of an endoluminal venous lesion (i.e., thrombus or Key Words: web). BCS is considered secondary when hepatic Budd-Chiari syndrome, Etiology, Diagnosis, Treat - venous outflow obstruction originates from a le - ment; review . sion outside the venous system (tumor, abscess, cysts). The lesions can obstruct outflow by invad - ing the lumen or by extrinsic compression. According to the clinical manifestations, BCS Introduction can be divided into two groups: asymptomatic and symptomatic. BCS is considered asympto - Budd-Chiari syndrome (BCS) is defined as he - matic when there are no remarkable signs 6. patic venous outflow obstruction at any levels About 15%-20% of BCS patients are asympto - from the small hepatic veins (HV) to the junction matic. The major compensation mechanism of the inferior vena cava (IVC) and the right atri - should be the spontaneous development of large um, regardless of the cause of obstruction 1-3 . intra- or extra-hepatic and portosystemic collater - However, hepatic venous outflow obstructions als 7. By comparison, most of BCS patients are caused by hepatic veno-occlusive disease/sinu - symptomatic. They include abdominal pain, as - soidal obstruction syndrome and cardiac disor - cites, jaundice, hepatomegaly, edema, en - ders should be excluded from this definition. cephalopathy and/or gastrointestinal bleeding. This is because veno-occlusive disease/sinusoidal According to the location of obstruction, BCS obstruction syndrome refers to the obstruction of is briefly classified as three types: pure obstruc - sinusoids or central hepatic veins due to toxic in - tion of HVs, pure obstruction of IVC, and com - Corresponding Author: Guohong Han, MD; e-mail: [email protected] 3273 L. Liu, X.-S. Qi, Y. Zhao, H. Chen, X.-C. Meng, G.-H. Han bined obstruction of HVs and IVC 8. Pure IVC or ditional acquired risk factors should be clearly combined IVC/HV obstruction is common in recognized, such as oral contraceptive use and Asian countries 9, whereas pure HV obstruction is pregnancy 35-38 . frequent in Western countries. Given the nature Factor V Leiden mutation and prothrombin of obstruction, BCS is further classified as two G20210A gene mutation are considered as the major groups: (1) HV and/or IVC obstruction or most common inherited prothrombotic factors in thrombosis; and (2) HV and/or IVC webs. BCS patients 39-42 . However, a recent systematic review and meta-analysis suggests that the factor Etiology V Leiden mutation is associated with an in - One or more underlying prothrombotic condi - creased risk of BCS, but not the prothrombin tions are observed in at least 75% of patients G20210A mutation 43,44 . Thus, routine screening with primary BCS 10,11 . The systemic prothrom - for prothrombin G20210A mutation in BCS pa - botic conditions are divided into acquired and in - tients is questioned. Additionally, both gene mu - herited types. Acquired causes primarily include tations were hardly observed in Chinese patients myeloproliferative neoplasms (MPNs), hyperho - with BCS. To our knowledge, only few patients mocysteinemia, paroxysmal nocturnal hemoglo - with familial BCS presented with factor V Lei - binuria (PNH) and Behçet’s syndrome, etc. In - den mutation 45 . herited causes primarily include factor V Leiden Inherited protein C, protein S, and antithrom - mutation, G20210A prothrombin gene mutation bin deficiencies are also considered as the major and inherited protein C, protein S, and antithrom - risk factors for BCS. However, their roles are bin deficiencies. ambiguous, because chronic liver diseases often BCR-ABL negative MPNs, including poly - obscure the recognition of these deficiencies. cythemia vera, essential thrombocythemia, and Recently, a systematic review and meta-analysis idiopathic myelofibrosis, are the most common confirms that inherited protein C, protein S, or acquired causes of primary BCS 12,13 . The preva - antithrombin deficiencies should significantly lence of MPNs is about 50% in BCS patients 14 . increase the risk of BCS 46 Accordingly, the Because JAK2 V617F mutation is found in about measurement of protein C, protein S, or an - 80% of patients with polycythemia vera and 50% tithrombin concentrations should be regularly of patients with essential thrombocythemia or id - performed in BCS patients and their first-degree iopathic myelofibrosis, routine screening for JAK relatives. V617F mutation is very valuable to establish an Besides, the coagulation and fibrinolysis ab - early diagnosis of MPNs in BCS patients. Nu - normalities are found. In our recent study, the pa - merous observational studies and meta-analyses tients with BCS had significantly higher factor confirm that the JAK2 V617F mutation can be VIII levels and significantly lower factor V, VII, detected in 30-50% of BCS patients 15-19 . Howev - IX, X, XI, XII, protein C and antithrombin levels er, it should be noted that MPNs are rare in Chi - than healthy controls. This finding suggests an nese patients with BCS 20-24 . These findings sug - imbalance of pro- and anti-coagulation factors in gest that MPNs may not be a major etiology of BCS patients 47 . Additionally, a slightly increased BCS in China. fibrinolytic potential was observed in BCS pa - By comparison, hyperhomocysteinemia, PNH , tients 48 . and Behçet’s syndrome appear to be relatively rare etiologies of BCS. However, several impor - Diagnosis tant points should be clearly recognized. First, a A diagnosis of BCS should be considered in systematic review and meta-analysis suggests all patients with acute or chronic liver disease, that hyperhomocysteinemia with homozygous especially when common causes for liver disease MTHFR mutation may be associated with the oc - have been ruled out. In other words, the patency currence of BCS 25 . However, the relevant evi - of HV and IVC may be considered as a part of dence originates from very limited data. Second, routine evaluation of liver diseases. PNH is an extremely rare condition 26-28 . Howev - Imaging tests play a crucial role in the early er, the presence of hepatic vein thrombosis is ex - diagnosis of BCS and assessment of location of traordinarily high in patients with PNH 29 . Third, obstruction 49-51 . There are various imaging Behçet’s syndrome is a well-recognized cause of modalities for the investigation of hepatic vascu - BCS 30,31 . However, this is frequently observed in lar patency, such as Doppler ultrasound, MRI and Turkey 32-33 , but not in other countries 34 . Some ad - computed tomography. Doppler ultrasound has a 3274 Budd-Chiari syndrome: current perspectives and controversies diagnostic sensitivity of over 85% and should be and location of outflow obstruction and measure - the first choice of imaging investigation 52,53 . The ment of HVs pressure. Liver biopsy is also useful major signs of BCS include no blood flow signal for the exclusion of veno-occlusive disease 57 . in the hepatic veins, intra- or extra-hepatic collat - eral circulation, a spider-web appearance located Treatment adjacently to the hepatic vein ostia and stagnant, Currently, a step-wise treatment strategy has and reversed or turbulent blood flow 54,55 . Com - been proposed and widely adopted
Load more

Recommended publications
  • What Is Dvt? Deep Vein Thrombosis (DVT) Occurs When an Abnormal Blood Clot Forms in a Large Vein
    What is DVt? Deep vein thrombosis (DVT) occurs when an abnormal blood clot forms in a large vein. These clots usually develop in the lower leg, thigh, or pelvis, but can also occur in other large veins in the body. If you develop DVT and it is diagnosed correctly and quickly, it can be treated. However, many people do not know if they are at risk, don’t know the symptoms, and delay seeing a healthcare professional if they do have symptoms. CAn DVt hAppen to me? Anyone may be at risk for DVT but the more risk factors you have, the greater your chances are of developing DVT. Knowing your risk factors can help you prevent DVt: n Hospitalization for a medical illness n Recent major surgery or injury n Personal history of a clotting disorder or previous DVT n Increasing age this is serious n Cancer and cancer treatments n Pregnancy and the first 6 weeks after delivery n Hormone replacement therapy or birth control products n Family history of DVT n Extended bed rest n Obesity n Smoking n Prolonged sitting when traveling (longer than 6 to 8 hours) DVt symptoms AnD signs: the following are the most common and usually occur in the affected limb: n Recent swelling of the limb n Unexplained pain or tenderness n Skin that may be warm to the touch n Redness of the skin Since the symptoms of DVT can be similar to other conditions, like a pulled muscle, this often leads to a delay in diagnosis. Some people with DVT may have no symptoms at all.
    [Show full text]
  • A 12-Years Rectal Bleeding Complicated with Deep Vein Thrombosis, Is Hemorrhoid the Real Cause?
    Case Report Clinical Case Reports Volume 10:11, 2020 DOI: 10.37421/jccr.2020.10.1395 ISSN: 2165-7920 Open Access A 12-Years Rectal Bleeding Complicated with Deep Vein Thrombosis, Is Hemorrhoid the Real Cause? Yi-Qun Zhang, Meng Niu and Chun-Xiao Chen* Department of Gastroenterology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P. R. China Abstract Colorectal venous malformation is a rare condition that can cause massive rectal bleeding. This is the first report of colorectal venous malformation complicated with massive bleeding and lowers limb deep vein thrombosis, and the two life-threatening conditions were both treated successfully. Keywords: Colorectal venous malformation • Rectal bleeding • Sclerotherapy • Deep vein thrombosis Introduction A 16-year-old man presented to the clinic with long-standing recurrent hematochezia and profound anemia. Per the mother, his rectal bleeding was first noticed around the age of 4 with one episode per 2-3 months that was diagnosed as hemorrhoids without specific treatment. It had worsened for 2 months with progression to 1 bloody bowel movement daily. He had no family history of hematologic disorders or vascular anomalies. The patient had accepted 600 ml red-blood cell perfusion and intravenous sucrose-iron transfusions for severe anemia with hemoglobin 5.8 g/dL, hematocrit 25.9% and MCV 69.7 fL at local hospital. Case Report Upon admission, the patient’s vital signs were within normal limits. His abdomen was supple and without tenderness. Digital rectal examination confirmed partially thrombosed, circumferential mixed hemorrhoids. Laboratory tests revealed a hemoglobin 8.0 g/L and D-dimer 15760 g/L.
    [Show full text]
  • Treatment Strategies for Patients with Lower Extremity Chronic Venous Disease (LECVD)
    Evidence-based Practice Center Systematic Review Protocol Project Title: Treatment Strategies for Patients with Lower Extremity Chronic Venous Disease (LECVD) Project ID: DVTT0515 Initial publication date if applicable: March 7, 2016 Amendment Date(s) if applicable: May 6th, 2016 (Amendments Details–see Section VII) I. Background for the Systematic Review Lower extremity chronic venous disease (LECVD) is a heterogeneous term that encompasses a variety of conditions that are typically classified based on the CEAP classification, which defines LECVD based on Clinical, Etiologic, Anatomic, and Pathophysiologic parameters. This review will focus on treatment strategies for patients with LECVD, which will be defined as patients who have had signs or symptoms of LE venous disease for at least 3 months. Patients with LECVD can be asymptomatic or symptomatic, and they can exhibit a myriad of signs including varicose veins, telangiectasias, LE edema, skin changes, and/or ulceration. The etiology of chronic venous disease includes venous dilation, venous reflux, (venous) valvular incompetence, mechanical compression (e.g., May-Thurner syndrome), and post-thrombotic syndrome. Because severity of disease and treatment are influenced by anatomic segment, LECVD is also categorized by anatomy (iliofemoral vs. infrainguinal veins) and type of veins (superficial veins, perforating veins, and deep veins). Finally, the pathophysiology of LECVD is designated typically as due to the presence of venous reflux, thrombosis, and/or obstruction. LECVD is common
    [Show full text]
  • Venous Ulcers: Diagnosis and Treatment
    Venous Ulcers: Diagnosis and Treatment Susan Bonkemeyer Millan, MD; Run Gan, MD; and Petra E. Townsend, MD University of Florida Health Wound Care and Hyperbaric Center and the University of Florida College of Medicine, Gainesville, Florida Venous ulcers are the most common type of chronic lower extremity ulcers, affecting 1% to 3% of the U.S. population. Venous hypertension as a result of venous reflux (incompetence) or obstruction is thought to be the primary underlying mechanism for venous ulcer formation. Risk factors for the development of venous ulcers include age 55 years or older, family history of chronic venous insufficiency, higher body mass index, history of pulmonary embolism or superficial/deep venous throm- bosis, lower extremity skeletal or joint disease, higher number of pregnancies, parental history of ankle ulcers, physical inactivity, history of ulcers, severe lipodermatosclerosis, and venous reflux in deep veins. Poor prognostic signs for heal- ing include ulcer duration longer than three months, initial ulcer length of 10 cm or more, presence of lower limb arterial disease, advanced age, and elevated body mass index. On physical examination, venous ulcers are generally irregular and shallow with well-defined borders and are often located over bony prominences. Signs of venous disease, such as varicose veins, edema, or venous dermatitis, may be present. Other associated findings include telangiectasias, corona phlebectatica, atrophie blanche, lipodermatosclerosis, and inverted champagne-bottle deformity of the lower leg. Chronic venous ulcers significantly impact quality of life. Severe complications include infection and malignant change. Current evidence supports treatment of venous ulcers with compression therapy, exercise, dressings, pentoxifylline, and tissue products.
    [Show full text]
  • Hypertension and the Prothrombotic State
    Journal of Human Hypertension (2000) 14, 687–690 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh REVIEW ARTICLE Hypertension and the prothrombotic state GYH Lip Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK The basic underlying pathophysiological processes related to conventional risk factors, target organ dam- underlying the major complications of hypertension age, complications and long-term prognosis, as well as (that is, heart attacks and strokes) are thrombogenesis different antihypertensive treatments. Further work is and atherogenesis. Indeed, despite the blood vessels needed to examine the mechanisms leading to this being exposed to high pressures in hypertension, the phenomenon, the potential prognostic and treatment complications of hypertension are paradoxically throm- implications, and the possible value of measuring these botic in nature rather than haemorrhagic. The evidence parameters in routine clinical practice. suggests that hypertension appears to confer a Journal of Human Hypertension (2000) 14, 687–690 prothrombotic or hypercoagulable state, which can be Keywords: hypercoagulable; prothrombotic; coagulation; haemorheology; prognosis Introduction Indeed, patients with hypertension are well-recog- nised to demonstrate abnormalities of each of these Hypertension is well-recognised to be an important 1 components of Virchow’s triad, leading to a contributor to heart attacks and stroke. Further- prothrombotic or hypercoagulable state.4 Further- more, effective antihypertensive therapy reduces more, the processes of thrombogenesis and athero- strokes by 30–40%, and coronary artery disease by 2 genesis are intimately related, and many of the basic approximately 25%. Nevertheless the basic under- concepts thrombogenesis can be applied to athero- lying pathophysiological processes underlying both genesis.
    [Show full text]
  • Thrombosis and Embolism After Injury J Clin Pathol: First Published As 10.1136/Jcp.S3-4.1.86 on 1 January 1970
    J. clin. Path., 23, Suppl. (Roy. Coll. Path.), 4, 86-101 Thrombosis and embolism after injury J Clin Pathol: first published as 10.1136/jcp.s3-4.1.86 on 1 January 1970. Downloaded from S. SEVITT From the Birmingham Accident Hospital Thrombosis is frequent in injured patients. It classified as follows, namely, local thrombosis, takes different forms, and at least one of them, deep vein thrombosis, pulmonary microem- deep vein thrombosis in the lower limbs, is a bolism, glomerular microthrombosis, allied to common cause of morbidity and death through the Schwartzman reaction, occasional cases of embolic detachment. The different kinds may be arterial thrombosis, and rarely, abacterial vege- tative endocarditis. Thrombi form in flowing blood and are layered structures, unlike blood clots which form copyright. in static blood. They contain platelets, fibrin, red cells, and leucocytes, or a variable mixture, the differences depending on size, genesis, age, and venous or arterial location; but whatever the origin, the building blocks of enlarging thrombi are closely packed clumps of platelets with narrow fibrin borders (Fig. 1). Two main pro- http://jcp.bmj.com/ cesses are involved, namely, coagulation and platelet aggregation. These are interlinked and local release of thrombin is probably the key factor; thrombin promotes platelet clumping at a low concentration and fibrin formation at a higher concentration. Further, the release of substances from platelets can set in motion the coagulation on September 30, 2021 by guest. Protected process. Local Thrombosis and Haemostasis Thrombosis is frequent as a direct response to injury. In burned skin, for example, small venous thrombi may become prominent in the subdermis and subcutaneous tissue.
    [Show full text]
  • Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
    How can it be prevented? You can take steps to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). If you're at risk for these conditions: • See your doctor for regular checkups. • Take all medicines as your doctor prescribes. • Get out of bed and move around as soon as possible after surgery or illness (as your doctor recommends). Moving around lowers your chance of developing a blood clot. References: • Exercise your lower leg muscles during Deep Vein Thrombosis: MedlinePlus. (n.d.). long trips. Walking helps prevent blood Retrieved October 18, 2016, from clots from forming. https://medlineplus.gov/deepveinthrombos is.html If you've had DVT or PE before, you can help prevent future blood clots. Follow the steps What Are the Signs and Symptoms of Deep above and: Vein Thrombosis? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from • Take all medicines that your doctor http://www.nhlbi.nih.gov/health/health- prescribes to prevent or treat blood clots topics/topics/dvt/signs • Follow up with your doctor for tests and treatment Who Is at Risk for Deep Vein Thrombosis? - • Use compression stockings as your DEEP NHLBI, NIH. (n.d.). Retrieved October 18, doctor directs to prevent leg swelling 2016, from http://www.nhlbi.nih.gov/health/health- VEIN topics/topics/dvt/atrisk THROMBOSIS How Can Deep Vein Thrombosis Be Prevented? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from (DVT) http://www.nhlbi.nih.gov/health/health- topics/topics/dvt/prevention How Is Deep Vein Thrombosis Treated? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from http://www.nhlbi.nih.gov/health/health- topics/topics/dvt/treatment Trinity Surgery Center What is deep vein Who is at risk? What are the thrombosis (DVT)? The risk factors for deep vein thrombosis symptoms? (DVT) include: Only about half of the people who have DVT A blood clot that forms in a vein deep in the • A history of DVT.
    [Show full text]
  • Budd-Chiari Syndrome Secondary to Catheter-Associated Inferior Vena
    CASE REPORT | RELATO DE CASO Budd-Chiari syndrome secondary to catheter-associated inferior vena cava thrombosis Síndrome de Budd-Chiari secundária a trombose de veia cava inferior associada a cateter Authors ABSTRACT RESUMO Gustavo N. Araujo 1 Luciane M. Restelatto 1 Introduction: Patients with chronic Introdução: Pacientes com doença renal crô- Carlos A. Prompt 1,2 kidney disease (CKD) are at increased nica (DRC) apresentam risco aumentado de Cristina Karohl 1,2 risk for thrombotic complications. The complicações trombóticas e o uso de cateter use of central venous catheters as dialysis venoso central para realização de hemodiáli- vascular access additionally increases se aumenta este risco. Nós descrevemos um 1 Hospital de Clínicas de this risk. We describe the first case of caso de síndrome de Budd-Chiari (SBC) cau- Porto Alegre. Budd-Chiari syndrome (BCS) secondary sado pelo mal posicionamento de um cateter 2 Universidade Federal do to central venous catheter misplacement de diálise em um paciente com DRC e, para Rio Grande do Sul. in a patient with CKD. Case report: A nosso conhecimento, este é o primeiro caso 30-year-old female patient with HIV/AIDS relatado na literatura. Caso clínico: Paciente and CKD on hemodialysis was admitted feminina, 30 anos, com diagnóstico de HIV/ to the emergency room for complaints of SIDA e DRC em hemodiálise foi admitida fever, prostration, and headache in the na emergência com queixas de febre, pros- last six days. She had a tunneled dialysis tração e cefaleia há 6 dias. Ela apresentava catheter placed at the left jugular vein. um cateter de diálise tunelizado implantado The diagnosis of BCS was established 7 dias antes na veia jugular esquerda.
    [Show full text]
  • Deep Vein Thrombosis (DVT)
    Diseases and Conditions Deep vein thrombosis (DVT) By Mayo Clinic Staff Deep vein thrombosis (DVT) occurs when a blood clot (thrombus) forms in one or more of the deep veins in your body, usually in your legs. Deep vein thrombosis can cause leg pain or swelling, but may occur without any symptoms. Deep vein thrombosis can develop if you have certain medical conditions that affect how your blood clots. Deep vein thrombosis can also happen if you don't move for a long time, such as after surgery, following an accident, or when you are confined to a hospital or nursing home bed. Deep vein thrombosis is a serious condition because blood clots in your veins can break loose, travel through your bloodstream and lodge in your lungs, blocking blood flow (pulmonary embolism). Deep vein thrombosis signs and symptoms can include: Swelling in the affected leg. Rarely, there may be swelling in both legs. Pain in your leg. The pain often starts in your calf and can feel like cramping or a soreness. Deep vein thrombosis may sometimes occur without any noticeable symptoms. When to see a doctor If you develop signs or symptoms of deep vein thrombosis, contact your doctor for guidance. If you develop signs or symptoms of a pulmonary embolism — a life-threatening complication of deep vein thrombosis — seek medical attention immediately. The warning signs of a pulmonary embolism include: Unexplained sudden onset of shortness of breath Chest pain or discomfort that worsens when you take a deep breath or when you cough Feeling lightheaded or dizzy, or fainting Rapid pulse Coughing up blood Deep vein thrombosis occurs when a blood clot forms in the veins that are deep in your body, often in your legs.
    [Show full text]
  • Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism JASON WILBUR, MD, and BRIAN SHIAN, MD, Carver College of Medicine, University of Iowa, Iowa City, Iowa
    Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism JASON WILBUR, MD, and BRIAN SHIAN, MD, Carver College of Medicine, University of Iowa, Iowa City, Iowa Venous thromboembolism manifests as deep venous thrombosis (DVT) or pulmonary embolism, and has a mortal- ity rate of 6 to 12 percent. Well-validated clinical prediction rules are available to determine the pretest probability of DVT and pulmonary embolism. When the likelihood of DVT is low, a negative D-dimer assay result excludes DVT. Likewise, a low pretest probability with a negative D-dimer assay result excludes the diagnosis of pulmonary embo- lism. If the likelihood of DVT is intermediate to high, compression ultrasonography should be performed. Imped- ance plethysmography, contrast venography, and magnetic resonance venography are available to assess for DVT, but are not widely used. Pulmonary embolism is usually a consequence of DVT and is associated with greater mortality. Multidetector computed tomography angiography is the diagnostic test of choice when the technology is available and appropriate for the patient. It is warranted in patients who may have a pulmonary embolism and a positive D-dimer assay result, or in patients who have a high pre- test probability of pulmonary embolism, regardless of D-dimer assay result. Ventilation-perfusion scanning is an acceptable alternative to computed tomography angiography in select settings. Pulmonary angiography is needed only when the clinical suspicion for pulmo- nary embolism remains high, even when less invasive study results are negative. In unstable emergent cases highly suspicious for pulmo- nary embolism, echocardiography may be used to evaluate for right ventricular dysfunction, which is indicative of but not diagnostic for pulmonary embolism.
    [Show full text]
  • (I): Diagnosis, Treatment and Prognosis of Budd-Chiari Syndrome
    rEViEW Vascular liver disorders (i): diagnosis, treatment and prognosis of budd-Chiari syndrome J. Hoekstra, H.L.A. Janssen* Department of Gastroenterology and Hepatology, Erasmus Medical Center, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands, *corresponding author: room Ha 206, tel.: +31 (0)10-703 59 42, fax: +31 (0)10-436 59 16, e-mail: [email protected] AbsTract IntroductioN budd-Chiari syndrome (bCs) is a venous outflow obstruction Thrombosis involving the liver vasculature is rare but of the liver that has a dismal outcome if left untreated. Most constitutes a potentially life-threatening situation. cases of bCs in the Western world are caused by thrombosis of Budd-Chiari syndrome (BCS) is characterised by the hepatic veins, sometimes in combination with thrombosis thrombosis of the hepatic outflow tract. It is defined of the inferior vena cava. Typical presentation consists as a venous obstruction that can be located from the of abdominal pain, hepatomegaly and ascites, although level of the small hepatic veins up to the junction of the symptoms may vary significantly. Currently, a prothrombotic inferior vena cava with the right atrium (figure 1).1 Hepatic risk factor, either inherited or acquired, can be identified in outflow obstruction related to right-sided cardiac failure the majority of patients. Moreover, in many patients with bCs or sinusoidal obstruction syndrome (SOS, also known as a combination of risk factors is present. Myeloproliferative veno-occlusive disease)2 is not included in the definition of disorders are the most frequent underlying cause, occurring BCS. The clinical symptoms of BCS were first described by in approximately half of the patients.
    [Show full text]
  • Chapter 6: Clinical Presentation of Venous Thrombosis “Clots”
    CHAPTER 6 CLINICAL PRESENTATION OF VENOUS THROMBOSIS “CLOTS”: DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLUS Original authors: Daniel Kim, Kellie Krallman, Joan Lohr, and Mark H. Meissner Abstracted by Kellie R. Brown Introduction The body has normal processes that balance between clot formation and clot breakdown. This allows clot to form when necessary to stop bleeding, but allows the clot formation to be limited to the injured area. Unbalancing these systems can lead to abnormal clot formation. When this happens clot can form in the deep veins usually, but not always, in the legs, forming a deep vein thrombosis (DVT). In some cases, this clot can dislodge from the vein in which it was formed and travel through the bloodstream into the lungs, where it gets stuck as the size of the vessels get too small to allow the clot to go any further. This is called a pulmonary embolus (PE). This limits the amount of blood that can get oxygen from the lungs, which then limits the amount of oxygen that can be delivered to the rest of the body. How severe the PE is for the patient has to do with the size of the clot that gets to the lungs. Small clots can cause no symptoms at all. Very large clots can cause death very quickly. This chapter will describe the symptoms that are caused by DVT and PE, and discuss the means by which these conditions are diagnosed. What are the most common signs and symptoms of a DVT? The symptoms that are caused by DVT depend on the location and extent of the clot.
    [Show full text]